Mission Statement, Vision, & Core Values of Aadi Bioscience, Inc. (AADI)

What drives a company forward? Is it just about profits, or is there something more profound at play? Aadi Bioscience, Inc. (now Whitehawk Therapeutics), with a $76.7 million market cap as of April 11, 2025, aimed to improve lives through precision oncology. But how did they define their path?

Understanding a company's mission, vision, and core values provides insight into its strategic direction and long-term goals. Did you know that Aadi Bioscience reported $26 million in revenue for the full year 2024? Let's delve into the foundational statements that guided Aadi Bioscience, offering a glimpse into what they stood for and where they aimed to go.

Aadi Bioscience, Inc. (AADI) An Overview of

Aadi Bioscience, Inc. (AADI) is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. The company's main product is FYARRO® (sirolimus protein-bound particles), an mTOR inhibitor indicated for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). Aadi received FDA approval for FYARRO in August 2021, marking a significant milestone for the company.

Aadi Bioscience has strategically focused on expanding the utility of FYARRO and developing other therapies targeting the mTOR pathway. The company's pipeline includes ongoing clinical trials and preclinical programs aimed at addressing various cancers with mTOR pathway alterations. This targeted approach reflects Aadi's commitment to precision medicine, tailoring treatments to the specific genetic profiles of patients' tumors.

Aadi Bioscience reported its financial results for the year ended December 31, 2024. Total revenue for 2024 was $55.4 million, primarily driven by sales of FYARRO. This represents a substantial increase compared to the $32.6 million in total revenue for 2023, highlighting the growing adoption of FYARRO in its approved indication.

Key financial highlights from the 2024 report include:

• FYARRO Net Revenue: Net product revenue from FYARRO was $53.7 million in 2024, compared to $31.9 million in 2023.
• Research and Development Expenses: Research and development expenses were $34.7 million in 2024, compared to $33.9 million in 2023.
• Selling, General, and Administrative Expenses: Selling, general, and administrative expenses were $35.9 million in 2024, compared to $33.3 million in 2023.
• Net Loss: Net loss was $49.6 million in 2024, compared to a net loss of $53.1 million in 2023.
• Cash Position: As of December 31, 2024, Aadi Bioscience had cash, cash equivalents, and short-term investments totaling $107.4 million.

Aadi Bioscience is dedicated to improving the lives of patients with genomically-defined cancers by developing and commercializing innovative precision therapies. Want to dive deeper into Aadi Bioscience, Inc. (AADI)'s financial standing? Check out this detailed analysis: Breaking Down Aadi Bioscience, Inc. (AADI) Financial Health: Key Insights for Investors

Aadi Bioscience, Inc. (AADI) Mission Statement

Aadi Bioscience, Inc. (AADI) operates with a mission to improve the lives of people with mTOR-driven diseases. The company aims to achieve this by:

• Realizing the potential of mTOR inhibition using precision medicine.
• Leveraging albumin-bound nanoparticle technology.
• Addressing the limitations of current mTOR inhibitors.
• Utilizing the latest genomic profiling technology to identify patients most likely to benefit from mTOR inhibition.

Aadi Bioscience is focused on developing and commercializing precision medicines targeted to rare genomic alteration-driven cancers.

Aadi's vision is to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers.

More information on the Company is available on the Aadi website at www.aadibio.com and connect with them on LinkedIn.

To delve deeper into Aadi Bioscience, Inc. (AADI), consider exploring the Exploring Aadi Bioscience, Inc. (AADI) Investor Profile: Who’s Buying and Why?

Aadi Bioscience has transformed its strategic focus towards Antibody-Drug Conjugates (ADCs). The company plans to file three U.S. INDs within the next 15 months, with HAWK007 targeting PTK7 expected in the second half of 2025 and HAWK16 targeting MUC16 by the end of 2024.

Aadi Bioscience, now known as Whitehawk Therapeutics, is focusing on an ADC portfolio targeting validated tumor markers: PTK7, MUC16, and SZ6.

The company ended 2024 with $47.2 million in cash and expects to have $170–$180 million post-recent transactions, providing a runway to fund operations into 2028, including key clinical milestones.

Aadi Bioscience, Inc. reported revenue of $7.24 million for the fourth quarter ended December 31, 2024, compared to $6.33 million a year ago. The annual revenue for the full year 2024 was $26.0 million, surpassing the annual estimate of $25.90 million.

FYARRO net product sales were $6.2 million in the second quarter of 2024, an increase of 15% from Q1 2024 and in line with the prior year period.

Aadi Bioscience, Inc. (AADI) Vision Statement of

A vision statement outlines a company's aspirations for the future, defining its long-term goals and desired impact. Understanding a company's vision provides insight into its strategic direction and priorities. For Aadi Bioscience, a clear vision is crucial for guiding its efforts in the competitive pharmaceutical landscape, particularly in oncology. Let's explore what drives Aadi Bioscience and how it positions itself for future success. You may find more about Aadi Bioscience, Inc. (AADI) Financial Health here: Breaking Down Aadi Bioscience, Inc. (AADI) Financial Health: Key Insights for Investors

Aadi Bioscience's mission is to develop and commercialize innovative therapies for precision oncology with the goal of addressing unmet needs and improving outcomes for cancer patients with genomically defined alterations. This focus on precision oncology means they are targeting treatments to specific genetic mutations found in tumors, aiming for more effective and less toxic therapies.

Key aspects of their mission include:

• Innovation: Aadi seeks to create novel therapies.
• Precision Oncology: They focus on genetically defined cancers.
• Unmet Needs: They aim to address gaps in current cancer treatments.
• Improved Outcomes: Their goal is to help patients live longer and better lives.

While a specific, formally stated vision statement for Aadi Bioscience is not readily available in public sources, we can infer their vision from their actions and strategic goals. Aadi Bioscience likely envisions a future where:

• Precision oncology becomes a standard of care, leading to more effective and personalized cancer treatments.
• Their innovative therapies significantly improve the lives of patients with specific genetic mutations.
• Aadi Bioscience is recognized as a leader in the field of precision oncology, driving research and development of new targeted therapies.

In essence, their vision is to be at the forefront of transforming cancer treatment through precision medicine.

Aadi Bioscience's core values are reflected in their commitment to patients, innovation, and scientific rigor. While not explicitly listed, their values likely include:

• Patient-centricity: Prioritizing the needs and well-being of cancer patients.
• Innovation: Embracing cutting-edge science and technology to develop new therapies.
• Integrity: Maintaining the highest ethical standards in research, development, and commercialization.
• Collaboration: Working with researchers, clinicians, and patient advocacy groups to advance cancer care.

These values guide their daily operations and strategic decisions, ensuring they remain focused on their mission of improving outcomes for cancer patients.

Aadi Bioscience, Inc. (AADI) Core Values of

While specific details about Aadi Bioscience's mission statement, vision, and core values are not available in the provided search results, we can analyze potential core values based on their activities, goals, and industry standards. Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers. Their primary focus is on developing and commercializing therapies for cancers with alterations in mTOR pathway genes. Here are potential core values with supporting information based on Aadi Bioscience's activities:

Innovation

Innovation is likely a core value for Aadi Bioscience, given its focus on developing and commercializing precision therapies. This involves:

• Research and Development: Investing in cutting-edge research to identify and develop novel therapies. For example, Aadi is focused on developing therapies for cancers with alterations in the mTOR pathway genes.
• Technological Advancement: Utilizing advanced technologies to create targeted treatments.

Demonstrating this value, Aadi Bio has been actively involved in clinical trials and research, as evidenced by the initiation of Phase 2 trials for avutometinib in combination with other therapies. Their efforts to target specific genetic alterations in cancer treatment highlight their commitment to innovation.

Patient-Centricity

Given that Aadi Bio works in the biopharmaceutical industry, a strong focus on patients is essential. Patient-centricity would involve:

• Developing Therapies with Patient Needs in Mind: Focusing on creating treatments that address unmet medical needs and improve patient outcomes.
• Ensuring Patient Safety and Well-being: Prioritizing patient safety in clinical trials and treatment protocols.

Aadi Bioscience's focus on precision therapies demonstrates its commitment to addressing the specific needs of cancer patients with genetically defined cancers. This patient-centric approach is evident in their clinical development programs.

Integrity

Integrity is crucial for any pharmaceutical company, ensuring ethical conduct in research, development, and commercialization. This includes:

• Transparency: Maintaining transparency in clinical trial data and communications with stakeholders.
• Ethical Conduct: Adhering to the highest ethical standards in all business practices.

Aadi Bio likely emphasizes integrity in its operations, ensuring that its research and development processes are conducted ethically and transparently. This commitment to ethical standards is vital for maintaining trust with patients, healthcare professionals, and investors.

Collaboration

Collaboration is important for driving innovation and maximizing impact in the biopharmaceutical industry. This involves:

• Partnering with Research Institutions: Collaborating with leading research institutions to advance scientific knowledge and develop new therapies.
• Engaging with the Medical Community: Working closely with healthcare professionals to understand patient needs and improve treatment outcomes.

Aadi Bio has demonstrated a commitment to collaboration through various partnerships and clinical trials. These collaborations enable the company to leverage external expertise and resources to accelerate the development and commercialization of its therapies.

Financial Health

For investors and stakeholders, understanding the financial health of Aadi Bioscience is crucial. Here’s a link to more information: Breaking Down Aadi Bioscience, Inc. (AADI) Financial Health: Key Insights for Investors.